Dong-A Socio Holdings posted solid results last year, backed by steady growth across its major operating subsidiaries.


According to Dong-A Socio Holdings on February 9, on a consolidated basis the company recorded sales of 1.4298 trillion won last year, up 7.2% from 1.3332 trillion won a year earlier. In particular, operating profit surged 19.1% year-on-year from 82.1 billion won to 97.8 billion won, marking a significant improvement in profitability.

Exterior view of Dong-A Socio Holdings building in Dongdaemun-gu, Seoul. Dong-A Socio Holdings

Exterior view of Dong-A Socio Holdings building in Dongdaemun-gu, Seoul. Dong-A Socio Holdings

View original image

This performance growth was underpinned by balanced contributions from all business segments, including healthcare, biopharmaceutical CMO (contract manufacturing), and logistics. First, Dong-A Pharmaceutical stood out with steep growth in its over-the-counter (OTC) medicines segment. Sales rose 7.0% year-on-year to 726.3 billion won, while operating profit increased 2.0% to 86.9 billion won. In particular, sales in the OTC business segment jumped 26.4% from the previous year to 223.9 billion won, leading overall growth, and sales of the flagship product Bacchus also climbed 2.1% to 270.0 billion won.


STgen Bio, the biopharmaceutical CMO subsidiary, delivered the fastest growth. Revenue came in at 103.7 billion won, up 76.2% from a year earlier, and operating profit soared 323.4% year-on-year to 7.1 billion won. The global commercialization of the Stelara biosimilar and the securing of new contract volumes were the key drivers of this performance. Yongma Logis, which is in charge of the logistics business, also maintained stable growth, posting sales of 423.8 billion won (up 5.8%) and operating profit of 21.0 billion won (up 10.6%) through the acquisition of new shippers and expansion of its logistics scope.


Meanwhile, in the fourth quarter of 2025, the company continued to expand its top line, with sales rising 7.2% year-on-year to 371.9 billion won. However, operating profit fell 26.4% from a year earlier to 16.0 billion won. This decline is analyzed as being driven by a base effect from one-off tax refunds booked at Dong-A Pharmaceutical in the previous year, as well as an operating loss at STgen Bio stemming from one-off expenses.



A Dong-A Socio Holdings official said, "Strengthening the core competitiveness of our main operating subsidiaries and bringing the bio CMO business onto a full-fledged growth track drove the overall improvement in results," adding, "We will continue to pursue growth through ongoing expansion of new orders and business diversification going forward."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing